Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.
|Autori:||Wang, Yongjun; Pan, Yuesong; Li, Hao; Amarenco, Pierre; Denison, Hans; Evans, Scott R; Himmelmann, Anders; James, Stefan; Birve, Filip; Ladenvall, Per; Molina, Carlos A; Johnston, S Claiborne; Mancuso, Michelangelo; THALES Steering Committee and, Investigators|
|Titolo:||Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial|
|Anno del prodotto:||2021|
|Digital Object Identifier (DOI):||10.1001/jamaneurol.2021.2440|
|Appare nelle tipologie:||1.1 Articolo in rivista|